JETEMA, Co., Ltd. (216080.KQ)
KRW 15130.0
(-2.64%)
KRW 15130.0
(-2.64%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 13.96 Billion KRW | 859.85% |
| 2022 | 1.45 Billion KRW | -86.63% |
| 2021 | 10.88 Billion KRW | 216.7% |
| 2020 | -9.32 Billion KRW | 36.66% |
| 2019 | -14.72 Billion KRW | 6.52% |
| 2018 | -15.75 Billion KRW | -182.12% |
| 2017 | -5.58 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -32.14 Million KRW | 97.71% |
| 2024 Q1 | -1.4 Billion KRW | -105.57% |
| 2023 Q1 | -1.63 Billion KRW | 84.7% |
| 2023 Q3 | -3.58 Billion KRW | 40.9% |
| 2023 Q2 | -6.06 Billion KRW | -270.84% |
| 2023 FY | 13.96 Billion KRW | 859.85% |
| 2023 Q4 | 25.25 Billion KRW | 804.2% |
| 2022 Q2 | 8.3 Billion KRW | 131.86% |
| 2022 Q1 | 3.58 Billion KRW | -69.5% |
| 2022 Q3 | 259.1 Million KRW | -96.88% |
| 2022 FY | 1.45 Billion KRW | -86.63% |
| 2022 Q4 | -10.69 Billion KRW | -4228.65% |
| 2021 Q3 | -2.59 Billion KRW | -807.32% |
| 2021 Q4 | 11.75 Billion KRW | 553.21% |
| 2021 Q1 | 1.36 Billion KRW | 703.36% |
| 2021 FY | 10.88 Billion KRW | 216.7% |
| 2021 Q2 | 366.55 Million KRW | -73.05% |
| 2020 Q3 | -2.13 Billion KRW | 52.65% |
| 2020 Q1 | -2.83 Billion KRW | 44.07% |
| 2020 FY | -9.32 Billion KRW | 36.66% |
| 2020 Q4 | 169.3 Million KRW | 107.91% |
| 2020 Q2 | -4.51 Billion KRW | -59.25% |
| 2019 Q3 | -2.69 Billion KRW | 0.0% |
| 2019 FY | -14.72 Billion KRW | 6.52% |
| 2019 Q4 | -5.07 Billion KRW | -88.58% |
| 2019 Q1 | -2.79 Billion KRW | 0.0% |
| 2018 Q1 | -935.47 Million KRW | 0.0% |
| 2018 FY | -15.75 Billion KRW | -182.12% |
| 2017 FY | -5.58 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 107.386% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | 244.047% |
| BINEX Co., Ltd. | 4.67 Billion KRW | -199.008% |
| Bioneer Corporation | -10.58 Billion KRW | 231.915% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | 591.61% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | -139.142% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 128.546% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 121.792% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | 265.645% |
| Medy-Tox Inc. | 9.75 Billion KRW | -43.165% |
| Peptron, Inc. | -15.92 Billion KRW | 187.715% |
| Amicogen, Inc. | -23.28 Billion KRW | 159.968% |
| Genexine, Inc. | -66.87 Billion KRW | 120.884% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | 706.644% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 118.949% |
| ALTEOGEN Inc. | -3.37 Billion KRW | 514.202% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 81.756% |
| SillaJen, Inc. | -20.36 Billion KRW | 168.564% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | 173.113% |
| Genomictree Inc. | -8.75 Billion KRW | 259.5% |
| MedPacto, Inc. | -35.32 Billion KRW | 139.536% |
| D&D Pharmatech | 3.93 Billion KRW | -255.023% |
| EASY BIO,Inc. | 15.54 Billion KRW | 10.151% |
| GI Innovation, Inc. | -55.49 Billion KRW | 125.166% |